Experiments 26
Small Enough to HoldFour Ways to Be Wrong
Chemotherapy instilled into the peritoneal cavity diffuses into tumor nodules while capillary washout clears it, limiting penetration to roughly a millimeter. Adjust drug, nodule size, and dwell time below, or inspect claims pre-registered by the research agent against the same solver.
Python · FastAPI · DuckDB · PharmacokineticsView source
Four referees. One of them is arithmetic.
A core of 1.53 mm is never reached.
What the arithmetic says
- It gets
- 0.47 mm
- Never reached
- 1.53 mm
- Of the volume
- 55.5%
- Decay length
- 0.092 mm
- Front settled
- yes
- Above killing
- 129×
The sink is mostly the capillaries, which carry off about forty times what the cells consume. This reproduces a published model exactly. It is not a measurement: published figures for the same question run from about twenty micrometres to five millimetres, and the spread is mostly about what each study counted as arriving. Read this as a scale.
Waking
- waiting
No rules yet.
- Sealed
- 0
- Held
- 0
- Broken
- 0
- Refused
- 0
What the kernel reproduces
| Drug | It says | Published | In band |
|---|---|---|---|
| Cisplatin | 0.453 mm | 0.36–0.49 mm | yes |
| Paclitaxel | 0.593 mm | 0.54–0.75 mm | yes |
Steuperaert 2017, from its own cited parameters, with nothing fitted. Reproducing a model proves the code, not the physics, so this referee may refuse a claim but may not earn with one until it is gated against measured depths.
The four referees
| Referee | Asks | State |
|---|---|---|
| Reach | Can it get there? | not checked |
| Kill | Do the cells need it? | not checked |
| Matter | Does it show up in people? | not checked |
| Later | What will the trials report? | not checked |
Each gate is ground truth something else already fixed. Kill separates 1523 genes known to be needed by every cell from 726 known to be dispensable, at 0.9991 across 63 colorectal lines. Matter has to see checkpoint drugs run 5.07 times longer in mismatch-repair-defective disease, and stay quiet on a drug that should show nothing. Later has no opinion to check: a bet on a trial that has not reported is sealed and left open, sometimes for years. Reach passes neither, so it may refuse a claim and never earn with one.
What it has sealed
| Claim | Said | Found | Bits |
|---|---|---|---|
Notes
Reaction-diffusion model
Intraperitoneal drug diffuses inward from the nodule surface while capillary washout clears it at rate k (roughly 40× cellular uptake), giving a characteristic decay length √(D/k). Effective penetration depth scales with that length times the log ratio of bath concentration to IC50. Once k · t exceeds ~3, the concentration profile reaches steady state and longer dwell times add negligible depth.
Literature calibration
Without parameter fitting, the solver matches published model depths for cisplatin (0.453 mm vs. 0.36–0.49 mm) and paclitaxel (0.593 mm vs. 0.54–0.75 mm). However, nine experimental penetration measurements in the literature span 20 µm to 5 mm (a 250× range) due to differing assay endpoints and systemic vascular delivery. Because a 0.5 mm prediction trivially falls inside that span, this referee can falsify bad arithmetic but cannot award discovery credit.
Knockout screen referee
The gene-essentiality referee scores 63 colorectal cell lines in DepMap, separating known core-essential and non-essential gene sets at AUROC 0.9991. However, only six screened lines derive from peritoneal metastases (representing five unique patients, below the pre-registered minimum sample size), and none appear in the PRISM drug-sensitivity screen. Per-site comparisons are therefore withheld automatically.
Pre-registered claims
The agent must seal every claim with a quantitative threshold and a probability before a referee executes. Claims are scored strictly on calibration and information gain over prior baseline bounds, and untestable claims are recorded as refused rather than retried.